Penela Diego, Acosta Juan, Aguinaga Luis, Tercedor Luis, Ordoñez Augusto, Fernández-Armenta Juan, Andreu David, Sánchez-Millán Pablo J, Cabanelas Nuno, Tolosana Jose Maria, Vassanelli Francesca, Cabrera Mario, Korshunov Viatcheslav, Sitges Marta, Brugada Josep, Mont Lluis, Berruezo Antonio
Cardiology Department, Thorax Institute, Hospital Clínic and IDIBAPS (Institut d'Investigació Agustí Pi i Sunyer), Barcelona, Catalonia, Spain.
Private Cardiology Center, Tucuman, Argentina.
Heart Rhythm. 2015 Dec;12(12):2434-42. doi: 10.1016/j.hrthm.2015.09.011. Epub 2015 Sep 15.
Premature ventricular complex (PVC) ablation has been shown to improve left ventricular ejection fraction (LVEF) and New York Heart Association functional class in patients with left ventricular dysfunction. Both are considered key variables in predicting risk of sudden cardiac death.
The objective of this study was to assess whether ablation might remove the primary prevention (PP) implantable cardioverter-defibrillator (ICD) indication in patients with frequent PVC.
Sixty-six consecutive patients with PP-ICD indication and frequent PVC [33 (50%) men; mean age 53 ± 13 years; 11 (17%) with ischemic heart disease] underwent PVC ablation. The ICD was withheld and the indication was reevaluated at 6 and 12 months.
LVEF progressively improved from 28% ± 4% at baseline to 42% ± 12% at 12 months (P < .001). New York Heart Association functional class improved from 2 patients with NYHA functional class I (3%) at baseline to 35 (53%) at 12 months (P < .001). The brain natriuretic peptide level decreased from 246 ± 187 to 176 ± 380 pg/mL (P = .004). The PP-ICD indication was removed in 42 patients (64%) during follow-up, from 38 (92%) of them at 6 months, showing an independent association with baseline PVC burden and successful sustained ablation. In patients with successful sustained ablation, a cutoff value of 13% PVC burden had a sensitivity of 100% and a specificity of 93% (area under the curve 99%) for removing ICD indication postablation. No sudden cardiac deaths or malignant ventricular arrhythmias were observed.
In patients with frequent PVC and PP-ICD indication, ablation improves LVEF and, in most cases, allows removal of the indication. Withholding the ICD and reevaluating within 6 months of ablation seems to be a safe and appropriate strategy.
室性早搏(PVC)消融已被证明可改善左心室功能不全患者的左心室射血分数(LVEF)和纽约心脏协会功能分级。这两者均被视为预测心源性猝死风险的关键变量。
本研究的目的是评估消融是否可消除频繁PVC患者的一级预防(PP)植入式心脏复律除颤器(ICD)适应证。
66例连续的有PP-ICD适应证且频繁PVC的患者[33例(50%)为男性;平均年龄53±13岁;11例(17%)患有缺血性心脏病]接受了PVC消融。停用ICD,并在6个月和12个月时重新评估适应证。
LVEF从基线时的28%±4%逐渐改善至12个月时的42%±12%(P<.001)。纽约心脏协会功能分级从基线时2例纽约心脏协会功能I级(3%)改善至12个月时的35例(53%)(P<.001)。脑钠肽水平从246±187降至176±380 pg/mL(P=.004)。随访期间42例患者(64%)的PP-ICD适应证被消除,其中38例(92%)在6个月时消除,显示与基线PVC负荷和成功的持续性消融独立相关。在成功进行持续性消融的患者中,PVC负荷截断值为13%时,消融后消除ICD适应证的敏感性为100%,特异性为93%(曲线下面积99%)。未观察到心源性猝死或恶性室性心律失常。
在有频繁PVC和PP-ICD适应证的患者中,消融可改善LVEF,且在大多数情况下可消除适应证。停用ICD并在消融后6个月内重新评估似乎是一种安全且合适的策略。